Anti-CD20 therapy induces a memory Th1 response through the IFN-γ/IL-12 axis and prevents protumor regulatory T-cell expansion in mice
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-CD20 therapy induces a memory Th1 response through the IFN-γ/IL-12 axis and prevents protumor regulatory T-cell expansion in mice
Authors
Keywords
-
Journal
LEUKEMIA
Volume 29, Issue 4, Pages 947-957
Publisher
Springer Nature
Online
2014-09-18
DOI
10.1038/leu.2014.275
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses
- (2014) Xuanming Yang et al. CANCER CELL
- Essentials of Th17 cell commitment and plasticity
- (2013) P. Muranski et al. BLOOD
- Effective Anti-Neu-Initiated Antitumor Responses Require the Complex Role of CD4+ T Cells
- (2013) E. D. Mortenson et al. CLINICAL CANCER RESEARCH
- Natural and Induced T Regulatory Cells in Cancer
- (2013) Dennis O. Adeegbe et al. Frontiers in Immunology
- Control of regulatory T cells is necessary for vaccine-like effects of antiviral immunotherapy by monoclonal antibodies
- (2012) R. Nasser et al. BLOOD
- Antibody-Based Immunotherapy of Cancer
- (2012) Louis M. Weiner et al. CELL
- Modulation of tumor immunity by therapeutic monoclonal antibodies
- (2011) Riad Abès et al. CANCER AND METASTASIS REVIEWS
- Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity
- (2011) Steve C. Lee et al. IMMUNOLOGIC RESEARCH
- Origins of CD4+ effector and central memory T cells
- (2011) Marion Pepper et al. NATURE IMMUNOLOGY
- Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
- (2011) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
- (2010) E. Mossner et al. BLOOD
- Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response
- (2010) R. Abes et al. BLOOD
- The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
- (2010) SaeGwang Park et al. CANCER CELL
- CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies
- (2010) Stephen A. Beers et al. SEMINARS IN HEMATOLOGY
- Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab
- (2009) S. P. Hilchey et al. BLOOD
- Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion
- (2009) R. Houot et al. BLOOD
- Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors
- (2008) J. D. Brody et al. BLOOD
- Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16
- (2008) Christophe de Romeuf et al. BRITISH JOURNAL OF HAEMATOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started